[The Expression and Clinical Significance of in Newly Diagnosed Acute Myeloid Leukemia Patients].

OBJECTIVE

To detect the expression level of T-complex polypeptide 1 (TCP1) in the bone marrow of newly diagnosed acute myeloid leukemia (AML) patients, and explore its correlation with clinical characteristics and prognosis.

METHODS

The bone marrow samples from 80 newly diagnosed AML patients and 30 iron deficiency anemia (IDA) patients were collected, and real time fluorescence quantitative PCR was used to detect the expression level of . The clinical data of AML patients were collected, and the correlation of expression with clinical characteristics and prognosis of patients were analyzed. The impact of on overall survival (OS) of AML patients was identified by using Kaplan-Meier curve analysis. Cox regression analysis was used to identify the factors affecting prognosis of AML patients.

RESULTS

Compared with IDA patients, the expression of was significantly increased in AML patients ( < 0.01). The high expression group of showed a higher proportion of patients with ≥60 years and non-remission after treatment, more accompanied by mutation and poor prognosis but shorter OS compared to the low expression group (all < 0.05). The results of multivariate Cox regression analysis showed that age, chromosomal abnormalities, therapeutic efficacy and expression were independent risk factors affecting prognosis of AML patients (all < 0.05).

CONCLUSION

is significantly upregulated in AML patients, and its expression is associated with partial clinical features and poor prognosis. It can serve as a prognostic indicator and potential therapeutic target for AML patients.